RemeGen Co., Ltd. Announces Significant Investment in Wealth Management Products
Key Points of the Announcement
- RemeGen Co., Ltd. (Stock Code: 9995) has announced a series of investments in wealth management products using idle self-owned funds, amounting to a total of RMB 538 million over several agreements with Huatai Securities Co., Ltd. (“HTSC”).
- The transactions have been classified as a discloseable transaction under Chapter 14 of the Hong Kong Stock Exchange Listing Rules due to their size, which may have implications for the company’s share price.
- The investments are part of the company’s strategy to enhance capital utilization and boost returns on idle funds while maintaining a controlled risk profile.
Details of the Wealth Management Product Transactions
At the 36th meeting of the second session of the Board on March 27, 2026, RemeGen approved a resolution permitting the company to utilize up to RMB 2.5 billion of idle self-owned funds for cash management, including the purchase of wealth management products.
Between May 14 and May 20, 2026, RemeGen entered into a total of eight agreements with HTSC for the purchase of various wealth management products:
- May 14, 2026:
- Agreement No. 1: RMB 60 million
- Agreement No. 2: RMB 75 million
- Agreement No. 3: RMB 102 million
- Agreement No. 4: RMB 216 million
- May 19, 2026:
- Agreement No. 5: RMB 15 million
- Agreement No. 6: RMB 20 million
- May 20, 2026:
- Agreement No. 7: RMB 20 million
- Agreement No. 8: RMB 30 million
The total outlay for these agreements is RMB 538 million.
Product Details
HTSC Wealth Management Product Agreement No. 7:
– Product: Xiamen Trust – Hongyun Xiangtai No.11 Asset Management Trust Product
– Type: Fixed-Income Collective Fund Trust Plan
– Risk: Medium
– Principal: RMB 20 million
– Tenor: Expected duration 36 months
– Investment Scope: Consumer loan assets via revolving purchase
– Yield: Market-linked, subject to fluctuation
– Early Termination: Trustee has the right as per agreement
HTSC Wealth Management Product Agreement No. 8:
– Product: Shengxinxiang – Huatai WEFUND Private FOF 1067 Separate Asset Management Plan
– Type: Mixed
– Risk: Medium
– Principal: RMB 30 million
– Tenor: 10 years (actual period subject to subscriber exit date)
– Investment Scope: Financial products and cash-type assets
– Yield: Market-linked, subject to fluctuation
– Early Termination: Administrator has the right as per agreement
Listing Rules Implications
The aggregate value of the transactions with HTSC over the 12-month period exceeded 5% of the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules), but is less than 25%. Therefore, these constitute a discloseable transaction and are subject to reporting and announcement requirements under the Listing Rules. Such transactions, when aggregated, are treated as one transaction for the purposes of the Listing Rules.
Strategic Rationale and Shareholder Impact
- The Board considers the investments to be in the interests of the company and its shareholders, citing improved returns compared to standard bank deposits and manageable risk.
- The investments are expected to enhance RemeGen’s ability to utilize idle funds efficiently, which could positively impact future earnings.
- The investments are all at arm’s length, and HTSC is an independent third party.
What Shareholders Should Know
- This series of transactions is a major deployment of company resources, which may affect the company’s cash position and investment returns.
- As these products are medium risk and the yields are market-linked, there is an element of uncertainty regarding the return on these investments.
- Any substantial positive or negative variation in returns relative to expectations could impact reported earnings and, in turn, share price.
- The company remains compliant with all Listing Rule requirements, and the board affirms that the terms of all agreements are fair and reasonable.
Company Background
RemeGen Co., Ltd. is a leading PRC-based biopharmaceutical company focused on innovative biologics in autoimmune, oncology, and ophthalmic diseases. Huatai Securities Co., Ltd. (HTSC) is a prominent securities company listed in both Shanghai and Hong Kong, offering a range of financial and wealth management services.
Conclusion
This announcement represents a significant financial maneuver for RemeGen, potentially impacting its financial performance and share price. Investors should monitor subsequent disclosures regarding the performance of these wealth management products and any material impact on the company’s results.
Disclaimer: This article is a summary and analysis of a public disclosure made by RemeGen Co., Ltd. Investors should refer to the official company filings and consult their financial advisors before making any investment decisions. The information provided herein does not constitute investment advice.
廣東話版本
榮昌生物（RemeGen）宣布重大財富管理產品投資
公告重點
- 榮昌生物股份有限公司（股份代號：9995）宣布使用閒置自有資金，與華泰證券（HTSC）簽訂一系列財富管理產品協議，合計投資達人民幣5.38億元。
- 由於金額規模，這些交易被歸類為須予披露交易，可能對公司股價構成影響。
- 相關投資屬於公司提升資金運用效率及提高閒置資金回報的策略，同時控制風險。
財富管理產品交易詳情
2026年3月27日，董事會批准動用不超過人民幣25億元閒置自有資金作現金管理，包括購買財富管理產品。
2026年5月14日至5月20日期間，公司一共與華泰證券簽訂八份協議：
- 2026年5月14日：
- 協議1：人民幣6,000萬元
- 協議2：人民幣7,500萬元
- 協議3：人民幣1.02億元
- 協議4：人民幣2.16億元
- 2026年5月19日：
- 協議5：人民幣1,500萬元
- 協議6：人民幣2,000萬元
- 2026年5月20日：
- 協議7：人民幣2,000萬元
- 協議8：人民幣3,000萬元
總投資額為人民幣5.38億元。
產品詳情
協議7：
– 產品名稱：廈門信託－鴻運翔泰11號資產管理信託產品
– 類型：固定收益集合資金信託計劃
– 風險：中等
– 本金：人民幣2,000萬元
– 期限：預計36個月
– 投資範圍：循環購買消費貸款資產
– 收益：隨市場波動，不確定
– 提前終止權：信託人有權按協議行使
協議8：
– 產品名稱：盛信享－華泰WEFUND私募FOF1067單一資產管理計劃
– 類型：混合型
– 風險：中等
– 本金：人民幣3,000萬元
– 期限：10年（實際以退出日為準）
– 投資範圍：金融產品及現金類資產
– 收益：隨市場波動，不確定
– 提前終止權：管理人有權按協議行使
上市規則影響
由於12個月內與華泰證券的交易總額超過5%但低於25%（根據上市規則第14.07條），因此構成須予披露交易，需履行報告及公告義務。所有交易會被視為一宗合併計算。
策略考慮及對股東影響
- 董事會認為，該等投資能提升閒置資金回報，風險可控，符合公司及股東整體利益。
- 公司期望透過這些投資提高資金使用效率，或將正面影響未來盈利。
- 所有交易均為公平、市場條款，華泰證券為獨立第三方。
股東須知
- 本次系列交易屬公司資源重大部署，或會影響現金流及投資回報。
- 產品屬中等風險，回報隨市況波動，存在不確定性。
- 回報如有大幅波動，將影響公司業績及股價。
- 公司嚴格遵守上市規則，董事會確認協議條款公平合理。
公司簡介
榮昌生物是一家以自體免疫、腫瘤及眼科創新生物藥為主的生物醫藥公司。華泰證券為中國知名證券公司，於上海及香港上市，提供多元化財富管理及金融服務。
結論
本公告屬公司重大財務動作，或對財務表現及股價產生影響。投資者應密切關注後續產品表現及對公司業績的實質影響。
免責聲明：本文為榮昌生物公告之整理及分析，僅供參考，投資者應參閱公司官方公告及諮詢財務顧問後再作投資決定，本文章不構成投資建議。
